Sandu Pharmaceuticals

Sandu Pharmaceuticals EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Sandu Pharmaceuticals (524703.BO) as of Nov 2, 2026 is 5.94. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 2,486.78 — a change of -99.76% (lower).

EV/FCF

5.94

YoY

-99.76%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Sandu Pharmaceuticals is 2026 5.94 . EV/FCF (Enterprise Value to Free Cash Flow) of Sandu Pharmaceuticals was 2025 2,486.78 . It decreases by -99.76% lower compared to the previous year.

The Sandu Pharmaceuticals EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
8.66 INR
Jan 1, 2020
5.22 INR
Jan 1, 2021
2.74 INR
Jan 1, 2022
259.09 INR
Jan 1, 2023
-35.13 INR
Jan 1, 2024
-46.52 INR
Jan 1, 2025
2,486.78 INR
Jan 1, 2026
5.94 INR
The Sandu Pharmaceuticals EV/FCF history
YEAREV/FCFYoY
5.94-99.76%
2,486.78-5,445.98%
-46.52+32.41%
-35.13-113.56%
259.09+9,360.62%
2.74-47.52%
5.22-39.75%
8.66-84.63%
56.34+466.21%
9.95-135.50%
-28.03-371.73%
10.32-148.84%
-21.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sandu Pharmaceuticals Stock analysis

What does Sandu Pharmaceuticals do? Sandu Pharmaceuticals Ltd is a Mumbai-based company operating in the Consumer Staples sector, specifically within the consumer products industry. Listed on September 26, 1994, the firm manufactures and markets Ayurvedic medicines. Its product portfolio spans digestive health, immunity, muscle and bone health, respiratory health, and general wellness. Specific offerings address conditions such as constipation, hyperacidity, asthma, and colds, while also covering female, male, and mother-and-child wellness. The company utilizes in-house know-how from Sandu Brothers Private Limited for production and distributes its goods, including immunity kits and power herbs, through e-commerce marketplaces. Sandu Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sandu Pharmaceuticals stock

EV/FCF (Enterprise Value to Free Cash Flow) of Sandu Pharmaceuticals is 5.94 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Sandu Pharmaceuticals changed from 2,486.78 to 5.94, representing a -99.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Sandu Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Sandu Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Sandu Pharmaceuticals

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Sandu Pharmaceuticals